MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) Stock
1 member of Congress disclosed 1 trade in MRVI since 2023: 0 purchases and 1 sale, most recently Daniel Goldman (sale, Apr 10, 2023). 5 of the hedge funds AlphaScala tracks reported MRVI in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $40.61M.
Which members of Congress traded MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)?
Most recent: Daniel Goldman (sale, Apr 10, 2023); records start Apr 10, 2023.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Dan Goldman D-NY · House | 2023-04-10 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 20, 2026.
See all MRVI political trades →Which hedge funds own MRVI?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 6.51M | $40.61M | +295% |
| Renaissance Technologies Jim Simons (founder) | 4.61M | $28.74M | +8% |
| Citadel Ken Griffin | 2.12M | $13.25M | +43% |
| Point72 Steve Cohen | 2.01M | $12.51M | -37% |
| Marshall Wace | 1.47M | $9.18M | -29% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →MRVI price chart
Powered by TradingViewWhat does MARAVAI LIFESCIENCES HOLDINGS, INC. do?
Maravai Lifesciences Holdings Inc. is a notable entity within the biotechnology and life sciences sector, primarily focused on providing critical products and services that advance scientific research and development. The company's main are the production of nucleic acids and biologics, which are essential components in fields such as drug development, diagnostics, and molecular testing. Maravai is deeply involved in supplying innovative solutions for the synthesis and modification of nucleic acids, enabling breakthroughs in messenger RNA (mRNA) technology, a key area in the development of vaccines and therapies. The company's operations are integral to various industries where precision and cutting-edge biological research are paramount. Its contributions have been particularly impactful in accelerating the development of vaccines and treatments in response to the global demand for advanced biopharmaceutical solutions. With a strong commitment to supporting scientific innovation, Maravai Lifesciences Holdings Inc. holds a significant role in the life sciences market, providing foundational tools that empower researchers and healthcare institutions worldwide to achieve advancements in health and medicine.